At UCB, how we do science – from discovery to development to delivery – has been transformed and redesigned around understanding the patient and their individual experience. For specific patient populations new to UCB – like Myasthenia gravis (MG) – this is especially important because no two experiences of this rare, neuromuscular condition are alike. In honor of Myasthenia Gravis Awareness Month, join us as we shine a spotlight to help spread awareness and empower people living with MG.

Every day, UCB researchers come to work driven by a singular purpose – to create value for people living with severe disease. That’s because, across the world, patients depend on the important work of scientific research to find new medical innovations that will help them achieve their goals. From the “breakthrough” moments in discovery, development, and delivery, we are dedicated to finding solutions for the unmet needs of patients.

Wake County, NC teachers visiting for UCB’s annual SummerSTEM day. (L to R) Andrew Oliver, Bruce Mamel, Michelle Woods, Sarah Brown, Ken Whisler, Cherilyn Murray, Antwanna Pegues Simmons, and Laura Williford.

At UCB, we are committed to accelerating scientific discoveries by supporting innovation — leading to the discovery of new solutions that help patients achieve their goals. As part this commitment, we believe it is important to support STEM education in our local communities to help inspire the next generation of scientists.

This Osteoporosis Awareness Month, UCB is pleased to collaborate with OpenIDEO , an open innovation platform, to launch the new Healthy Bones, Healthy Aging Challenge.

A key underserved patient population is women of childbearing age managing chronic conditions. In honor of Mother’s Day, Aimee Frank, Senior Director of Communications at the American Gastroenterological Association (AGA), shares about the IBD Parenthood Project, an effort led by the AGA with support by UCB, to help address the misperceptions women with inflammatory bowel disease and their healthcare providers experience throughout family planning.

UCB is committed to improving care and outcomes for patients across the axial spondyloarthritis spectrum of disease. So, for Spondyloarthritis Awareness Month, we’re shining a spotlight on Non-Radiographic Axial Spondyloarthritis (nr-axSpA).

Earlier this week, researchers from across UCB met in Washington, D.C. for the PhRMA Researcher Fly-In. While on Capitol Hill, the UCB team visited the offices of Representatives Doug Collins, Lucy McBath, and David Price, and Senators Johnny Isakson, Richard Burr, and Thom Tillis and walked their staff through the 15-year journey (on average) of how a new medicine is discovered, developed, and delivered at UCB. Each researcher, representing a different part of the drug development process, shared their personal stories about why they’re motivated each day to continue to innovate for patients.

We believe our ability to continue to innovate and create value for patients now and in the future will increasingly depend on our positive contributions to environmental sustainability.

At UCB, we are inspired by patients and driven by science to deliver what patients value. We are committed to continuously working to advance science and embrace new knowledge — leading to the discovery of new solutions that help patients achieve their goals.

2018 marked the 90th anniversary of UCB. Since our creation in 1928, UCB has been characterized by a strong entrepreneurial spirit, determination and resilience, long term views, and a strong belief science and innovation would improve humanity.